Longenesis announces a $1.2 million late seed round led by Rustam Gilfanov. One of the Managing Partners of the LongeVC investment fund, Ilya Suharenko, also took part in it bringing in his 17 years of expertise in conventional banking.
Longenesis is developing a digital toolkit to expedite biomedical research. Its goal is to promote patients’ participation and confidence of research organizations and study sponsors, as well as to help clinics and patient advocacy groups to disclose their patients and data to biomedical research in compliance with all legal requirements.
Extensive and accurate data sets have an impact on obtaining accurate biomedical data. In this regard, the introduction of digital technology and the demonstration of biomedical assets based on informed consents from patients will help minimize costs and accelerate researches, as well as focus on patients themselves.
This funding will help Longenesis to grow in important markets and expand using its 3 core products:
Longenesis Curator
Curator has the purpose to enable these kinds of institutions to distribute and accept collaborations on patient datasets.
As there is no identifying data, patient confidentiality is assured. However, the data-enhanced display and accessibility enable third parties to readily determine whether the data has relevance to their research initiatives saving their time, money, and efforts. It increases the possibilities for individualized research while obeying privacy and local regulatory provisions.
Researchers at universities, government organizations, and AI businesses can use the data.
Longenesis Themis
Themis is an API-based consent management platform for research and clinical trials. It permits patients to take proactive participation in research projects and to learn more about their contribution to them.
“Digital consent provides research participants with the flexible control over their participation in the study. By signing or revoking it at any moment, participants have the adjustability to regulate their engagement in the research. This boosts faith in researchers and science, as such,” Dr. Lilian Tzivian, Ph.D., a senior epidemiologist at the University of Latvia, said.
Longenesis Engage
Engage makes it easy to admit new patients with a single click on the URL of the research organization.
Engage also handles the follow-up inquiries for patients, and oversees their permission throughout their involvement in researches. It features exporting and monitoring capabilities that aid in the study’s overall progress.
Longenesis traction
The solutions that Longenesis has previously implemented include such services as data curation and patient engagement throughout the EU, the Middle East, and Asia involving many governments, biopharmaceutical companies, and academic consortia.
The business has also partnered with Medtronic. This experiment is testing the digitalization of patient involvement in research and advocacy projects.
According to Indra Stelmane, an endocrinologist, Ph.D., and the President of the Latvian Diabetes Federation: “Until now, advocacy has been an enormous effort for the patient group. Patients’ needs and wants should be taken seriously, and their best interests should always be placed first. Varying capacities and mistrust are among the variables that inhibit this process. That is why we are pleased to work with Longenesis. We think that patient engagement and data curation solutions will provide us with access to diabetes patients and research partners who can help them. With all the above said, we expect that the project will just be the beginning.”
Longenesis supporters
Longenesis is propelled by LongeVC, the investment fund that helps biotech businesses develop from idea to start-up.
The primary goal of LongeVC is to pick up longevity-focused enterprises. Garri Zmudze, MP of LongeVC, comments on this:
“Compliant access to clinical data and patient cohorts is important to all biotech and longevity-focused ventures. We anticipate that Longenesis will become a backbone of compliant biomedical data exploitation in the years ahead.”
The Venture Partner of LongeVC, Rustam Gilfanov, having focused on the significance of digitalization in biotech and medical research, remarked on the topic as follows:
“Biotechnology is advancing quickly now, with new technologies making manual methods obsolete. Many recent triumphs in AI-led drug development serve as a wonderful illustration of this. Access to biomedical data assets is critical for such advances to be reproducible and scalable to foster early-stage business development. That’s our future.”
